{
  "story_id": "801e7de7544b113abde31e186dcbb155",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-01T13:33:49.000Z",
  "content_hash": "81b8d306e7c171e4f707a376275e3a7ca2d9e944ba5bac864daec593d1f2adf3",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Italian startup Holifya raises €2M to scale AI obesity clinic",
    "dek": "Holifya, a female-led Italian startup, secured €2M funding to expand its AI-powered GLP-1 obesity care clinic in Milan.",
    "prose": "Holifya, a female-led Italian startup based in Milan, has raised €2 million in a fundraising round led by CDP Venture Capital's Nex... fund to expand its AI-powered GLP-1 obesity clinic. [^1]\n\nHolifya, a digital clinic in Italy focused on pharmacologic obesity treatment, raised €2 million in a funding round consisting of €1.6 million in equity and €0.4 million in debt capital and grants. [^2]\n\nThe proportion of eligible Italians who use GLP-1 drugs is less than 1%, whereas in the UK it is over 4%. [^3]\n\nAdoption of GLP-1 therapy in Italy remains low at less than 1% of eligible patients, compared to 2% in Germany and over 4% in the UK. [^4]\n\nHolifya's AI system integrates up to 3,000 biomarkers per patient, including genetic, blood chemistry, and anamnestic data, combined with behavioral and clinical information to personalize therapy. [^5]\n\nOver 23 million adults in Italy are overweight or obese, with approximately 11 million eligible for GLP-1 therapy, representing one of the largest pools in Europe. [^6]\n\nHolifya's AI-powered platform is designed to optimize patient care and drug management for obesity treatment. [^7]\n\nThe startup aims to scale its operations to increase access to GLP-1 drugs in Italy. [^8]",
    "cited": "[{\"statement\":\"Holifya, a female-led Italian startup based in Milan, has raised €2 million in a fundraising round led by CDP Venture Capital's Nex... fund to expand its AI-powered GLP-1 obesity clinic.\",\"source\":\"Tech Funding News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T08:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Tech Funding News\"]},{\"statement\":\"Holifya, a digital clinic in Italy focused on pharmacologic obesity treatment, raised €2 million in a funding round consisting of €1.6 million in equity and €0.4 million in debt capital and grants.\",\"source\":\"Tech.eu\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:33:49.000Z\",\"publisher_count\":1,\"sources\":[\"Tech.eu\"]},{\"statement\":\"The proportion of eligible Italians who use GLP-1 drugs is less than 1%, whereas in the UK it is over 4%.\",\"source\":\"Tech Funding News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T08:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Tech Funding News\"]},{\"statement\":\"Adoption of GLP-1 therapy in Italy remains low at less than 1% of eligible patients, compared to 2% in Germany and over 4% in the UK.\",\"source\":\"Tech.eu\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:33:49.000Z\",\"publisher_count\":1,\"sources\":[\"Tech.eu\"]},{\"statement\":\"Holifya's AI system integrates up to 3,000 biomarkers per patient, including genetic, blood chemistry, and anamnestic data, combined with behavioral and clinical information to personalize therapy.\",\"source\":\"Tech.eu\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:33:49.000Z\",\"publisher_count\":1,\"sources\":[\"Tech.eu\"]},{\"statement\":\"Over 23 million adults in Italy are overweight or obese, with approximately 11 million eligible for GLP-1 therapy, representing one of the largest pools in Europe.\",\"source\":\"Tech.eu\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:33:49.000Z\",\"publisher_count\":1,\"sources\":[\"Tech.eu\"]},{\"statement\":\"Holifya's AI-powered platform is designed to optimize patient care and drug management for obesity treatment.\",\"source\":\"Tech Funding News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T08:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Tech Funding News\"]},{\"statement\":\"The startup aims to scale its operations to increase access to GLP-1 drugs in Italy.\",\"source\":\"Tech Funding News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T08:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Tech Funding News\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "4ebc7b4f98492837d7b0e7cb5547914d",
      "thread_id": "ef547ffef1d39e69312c9a19d059297e",
      "thread_label": "CDP Venture Capital",
      "novelty": "UPDATE",
      "content_hash": "01fb663ddecb6c675d448d62b73a713587c4959b440d1fb2dae93d26bbe5d688",
      "last_published_at": "2026-09-01T13:33:49.000Z",
      "read_receipt": {
        "slice_hash": "7cc2cfeaa83a493f819c8993320c986b52ea8a4c8545b36b726e6545af56dd51",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDFUMTM6MTU6NDMuMDAwMDAwWiIsImlkIjoiZWQ3YWM5NzJhYmIyODNmNGU4ZGZlYzNkNWE2MjI1MmYiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDFUMTM6NTk6MDkuMDAwMDAwWiIsImlkIjoiZjA1MmUxZjQ1NjYwMTY4NzA3Nzg2NDYyMzA2NDIzNWEiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12017721,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "Tx-2k7FUXL9yhxRdwJcY-qYobOd77cCqgJGMy5gSwwA389Ny9iCT3Y-ihfvo1uzGXphQSnJrWjR6B4YuUg6sCQ",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-02T21:37:44.454Z"
  },
  "cited_facts": [
    {
      "statement": "Holifya, a female-led Italian startup based in Milan, has raised €2 million in a fundraising round led by CDP Venture Capital's Nex... fund to expand its AI-powered GLP-1 obesity clinic.",
      "source": "Tech Funding News",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T08:00:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Tech Funding News"
      ]
    },
    {
      "statement": "Holifya, a digital clinic in Italy focused on pharmacologic obesity treatment, raised €2 million in a funding round consisting of €1.6 million in equity and €0.4 million in debt capital and grants.",
      "source": "Tech.eu",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:33:49.000Z",
      "publisher_count": 1,
      "sources": [
        "Tech.eu"
      ]
    },
    {
      "statement": "The proportion of eligible Italians who use GLP-1 drugs is less than 1%, whereas in the UK it is over 4%.",
      "source": "Tech Funding News",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T08:00:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Tech Funding News"
      ]
    },
    {
      "statement": "Adoption of GLP-1 therapy in Italy remains low at less than 1% of eligible patients, compared to 2% in Germany and over 4% in the UK.",
      "source": "Tech.eu",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:33:49.000Z",
      "publisher_count": 1,
      "sources": [
        "Tech.eu"
      ]
    },
    {
      "statement": "Holifya's AI system integrates up to 3,000 biomarkers per patient, including genetic, blood chemistry, and anamnestic data, combined with behavioral and clinical information to personalize therapy.",
      "source": "Tech.eu",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:33:49.000Z",
      "publisher_count": 1,
      "sources": [
        "Tech.eu"
      ]
    },
    {
      "statement": "Over 23 million adults in Italy are overweight or obese, with approximately 11 million eligible for GLP-1 therapy, representing one of the largest pools in Europe.",
      "source": "Tech.eu",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:33:49.000Z",
      "publisher_count": 1,
      "sources": [
        "Tech.eu"
      ]
    },
    {
      "statement": "Holifya's AI-powered platform is designed to optimize patient care and drug management for obesity treatment.",
      "source": "Tech Funding News",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T08:00:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Tech Funding News"
      ]
    },
    {
      "statement": "The startup aims to scale its operations to increase access to GLP-1 drugs in Italy.",
      "source": "Tech Funding News",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T08:00:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Tech Funding News"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}